Condition
Pancreatic Ductal Adenocarcinoma (PDAC)
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 20 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
20 shown[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology IndicationsNCT07702292 · 2026-06-30
RECRUITINGBiomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid TumorsNCT07410494 · 2026-02-01
RECRUITINGStudy of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASNCT07435038 · 2026-01-29
RECRUITINGStudy of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid TumorsNCT07349537 · 2026-01-08
RECRUITINGA Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid MalignanciesNCT07223047 · 2025-11-25
RECRUITINGA Study of STRO-004 in Adults With Refractory/Recurrent Metastatic CancerNCT07227168 · 2025-11-07
RECRUITINGA Study of MT-4561 in Patients With Various Advanced Solid TumorsNCT06943521 · 2025-04-18
RECRUITINGStudy of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASNCT06895031 · 2025-03-31
RECRUITINGKO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsNCT06026410 · 2023-10-18
RECRUITINGStudy of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsNCT06040541 · 2023-09-07
RECRUITINGA Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid TumorsNCT05706129 · 2023-03-14
RECRUITINGStudy of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASNCT05379985 · 2022-05-31
RECRUITINGStudy of LT-010391 in Participants With KRAS G12D-Mutant Solid TumorsNCT07624214 · 2026-07-01
NOT_YET_RECRUITINGStudy of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)NCT06710132 · 2025-01-29
ACTIVE_NOT_RECRUITINGA Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D MutationNCT06599502 · 2024-10-18
TERMINATED"Effect of Screening Using Imaging (CT/ EUS) on Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC) in Patients With New Onset Diabetes (NOD)" - A Prospective Pilot Observational StudyNCT06044064 · 2023-12-01
NOT_YET_RECRUITINGA Study of [225Ac]-FPI-2059 in Adult Participants With Solid TumoursNCT05605522 · 2023-02-07
TERMINATEDGEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid TumorsNCT04083599 · 2019-09-17
ACTIVE_NOT_RECRUITINGA Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid TumorsNCT03811652 · 2018-12-20
COMPLETEDA Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.NCT03549000 · 2018-07-18
TERMINATEDCommon interventions
CetuximabDRUG3PembrolizumabDRUG3GemcitabineDRUG2RMC-6236DRUG2[111In]-FPI-2058DRUG1[177Lu]Lu-DPI-4452DRUG1[225]-FPI-2059DRUG1[68Ga]BED003DRUG1[68Ga]Ga-DPI-4452DRUG15-FUDRUG1A blood sample for CA 19-9 (cancer detection test)PROCEDURE1AdagrasibDRUG1AZD0022DRUG1BMS-986523DRUG1BPI-572270DRUG1CabozantinibDRUG1CarboplatinDRUG1CisplatinDRUG1daraxonrasibDRUG1DarlifarnibDRUG1Dual-Target Antigen-Selected CAR-NKBIOLOGICAL1EB-SELECT Single-Target CAR-NK CellsBIOLOGICAL1GEN1042BIOLOGICAL1JYP0015DRUG1LT-010391DRUG1
Leading sponsors
Revolution Medicines, Inc.
3
3B Pharmaceuticals GmbH
1
Asian Institute of Gastroenterology, India
1
AstraZeneca
1
Betta Pharmaceuticals Co., Ltd.
1
Blue Earth Diagnostics
1
Bristol-Myers Squibb
1
EMD Serono Research & Development Institute, Inc.
1
Essen Biotech
1
Genmab
1
Guangzhou JOYO Pharma Co., Ltd
1
Kura Oncology, Inc.
1
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
1
Lumara Bio Oncologics GmbH
1
MedImmune LLC
1
Trial status mix
RECRUITING12
TERMINATED3
ACTIVE_NOT_RECRUITING2
NOT_YET_RECRUITING2
COMPLETED1
Phase mix
PHASE117
PHASE210
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.